Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

Patients treated with Xofigo-Xtandi experienced a 5.6-month boost to median OS over those treated with Xtandi alone.

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

Mayo Clinic in Jacksonville, Fla., offers a minimally invasive procedure to stabilize bones weakened by metastatic cancer, a technique available at few U.S. centers. The photodynamic bone ...

For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

LOWCOUNTRY, S.C. (WCIV) — In light of Former President Joe Biden's recent prostate cancer diagnosis, medical professional Dr. David Geier joined "Good Morning Charleston" Monday to discuss the ...

Radiation therapy treats roughly two-thirds of all cancer patients, yet healthy tissue has always absorbed collateral damage ...

Cancer specialists have long known that anemia, caused by a lack of healthy red blood cells, can arise when cancer metastasizes to the bone, but it’s been unclear why. A research team led by Princeton ...